Quest Diagnostics Inc.

Quest Diagnostics' 20.8 P/E sits meaningfully above its healthcare services peers while the stock trades 44.7 RSI—solidly neutral territory without momentum in either direction. The $21.2B diagnostic giant shows minimal short interest at 3.22% of float, suggesting little squeeze potential, yet sits below its 52-week high despite valuation that appears stretched relative to sector comparables. The combination of elevated multiples with neutral momentum and absence of crowded positioning implies the market has already priced in optimistic expectations; any disappointment could expose the stock to meaningful reversion, while fresh catalysts would be needed to justify current valuation levels.